Leqembi
Eisai, Biogenās Leqembi reduces amyloid in Alzheimerās, but safety concerns remain
Amid mounting concerns regarding the potential strain on healthcare infrastructure due to Leqembi, a drug for Alzheimer’s disease, Eisai and ...
Ad Council and Alzheimer’s Association’s Fresh Push to Raise Alzheimer’s Awareness in Hispanic Community
The Ad Council and the Alzheimer’s Association (AA) have unveiled a poignant new slogan, “Some Things Come with Age,” designed ...
Biogen anticipates 1,000 further layoffs by 2025 as it navigates a “transition”
Source – Biogen During the announcement of its first-quarter earnings, Biogen revealed its strategic decision to discontinue the development of ...
Eisai Unveils Lecanemab’s Alzheimer’s Breakthrough at AAIC 2023
Source – Eisai July 20, 2023 Biogen revealed the results of a comprehensive analysis of the Phase III Clarity AD ...
How will Medicare be affected by the cost of Leqembi from Eisai and Biogen? Sen. Sanders is curious
Senator Bernie Sanders (I-Vt.) is increasing his pressure on the US Department of Health and Human Services (HHS) regarding the ...
Eisai and Biogen Embark on Full Launch of Leqembi Following Alzheimer’s Approval
Source – Eisai On July 6, 2023, Eisai and Biogen received full approval from the FDA for their Alzheimer’s disease ...
CMS unveils details of its registry strategy for drugs targeting Alzheimer’s disease
Centers for Medicare and Medicaid Services (CMS) reveals additional details regarding its controversial plan to mandate participation in a patient ...
FDA Advisory Committee Vote Validates LEQEMBI Alzheimer’s Treatment
Source: Eisai On June 9, 2023, the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) of the US Food ...
Eisai has requested to approve Leqembi, its therapy for Alzheimer’s disease, in South Korea
This filing comes just before an FDA advisory committee meeting, which has raised expectations of the drug receiving full approval ...
